[
    [
        {
            "time": "2018-01-03",
            "original_text": "Eli Lilly, AstraZeneca Shares Fall After Halting Alzheimer's Drug Test",
            "features": {
                "keywords": [
                    "Lilly",
                    "AstraZeneca",
                    "Shares",
                    "Fall",
                    "Halting",
                    "Alzheimer's",
                    "Drug",
                    "Test"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly, AstraZeneca Shares Fall After Halting Alzheimer's Drug Test",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "AstraZeneca, Lilly Join Others On Failed Alzheimer's Drug Heap",
            "features": {
                "keywords": [
                    "AstraZeneca",
                    "Lilly",
                    "Failed",
                    "Alzheimer's",
                    "Drug"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AstraZeneca, Lilly Join Others On Failed Alzheimer's Drug Heap",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "AstraZeneca, Lilly halt tests of experimental Alzheimer's treatment",
            "features": {
                "keywords": [
                    "AstraZeneca",
                    "Lilly",
                    "halt",
                    "tests",
                    "experimental",
                    "Alzheimer's",
                    "treatment"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AstraZeneca, Lilly halt tests of experimental Alzheimer's treatment",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "Allergan's Second Anti-CGRP Drug Positive in Mid-Stage Study",
            "features": {
                "keywords": [
                    "Allergan",
                    "Anti-CGRP",
                    "Drug",
                    "Positive",
                    "Mid-Stage",
                    "Study"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Allergan's Second Anti-CGRP Drug Positive in Mid-Stage Study",
                "Correlation": 4,
                "Sentiment": 8,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-07",
            "original_text": "Lilly & AstraZeneca Scrap Studies on Alzheimer's Candidate",
            "features": {
                "keywords": [
                    "Lilly",
                    "AstraZeneca",
                    "Scrap",
                    "Studies",
                    "Alzheimer's",
                    "Candidate"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Lilly & AstraZeneca Scrap Studies on Alzheimer's Candidate",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-08",
            "original_text": "Alzheimer's Research Stumbles Again: What's the Road Ahead?",
            "features": {
                "keywords": [
                    "Alzheimer's",
                    "Research",
                    "Stumbles",
                    "Road",
                    "Ahead"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "research"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Alzheimer's Research Stumbles Again: What's the Road Ahead?",
                "Correlation": 6,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-09",
            "original_text": "Lilly-AstraZeneca latest to abandon Alzheimer's drug trials",
            "features": {
                "keywords": [
                    "Lilly",
                    "AstraZeneca",
                    "abandon",
                    "Alzheimer's",
                    "drug",
                    "trials"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Lilly-AstraZeneca latest to abandon Alzheimer's drug trials",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-10",
            "original_text": "Another Alzheimer's Drug Fails as Lilly, Astra Halt Tests",
            "features": {
                "keywords": [
                    "Alzheimer's",
                    "Drug",
                    "Fails",
                    "Lilly",
                    "Astra",
                    "Halt",
                    "Tests"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Another Alzheimer's Drug Fails as Lilly, Astra Halt Tests",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-11",
            "original_text": "Update on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease",
            "features": {
                "keywords": [
                    "Phase",
                    "3",
                    "Clinical",
                    "Trials",
                    "Lanabecestat",
                    "Alzheimer's",
                    "Disease"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "clinical trials"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Update on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-12",
            "original_text": "[$$] AstraZeneca and Eli Lilly scrap Alzheimer’s drug trial",
            "features": {
                "keywords": [
                    "AstraZeneca",
                    "Eli",
                    "Lilly",
                    "scrap",
                    "Alzheimer’s",
                    "drug",
                    "trial"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "[$$] AstraZeneca and Eli Lilly scrap Alzheimer’s drug trial",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-13",
            "original_text": "AstraZeneca, Eli Lilly To Discontinue Lanabecestat Trials In Alzheimer's",
            "features": {
                "keywords": [
                    "AstraZeneca",
                    "Eli",
                    "Lilly",
                    "Discontinue",
                    "Lanabecestat",
                    "Trials",
                    "Alzheimer's"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AstraZeneca, Eli Lilly To Discontinue Lanabecestat Trials In Alzheimer's",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]